Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
复制标题
DOI：
10.3390/cancers12082299
复制
发表时间：
2020-08-01
期刊：
影响因子：
5.2
通讯作者：
Nakagawa, Takashi
中科院分区：
文献类型：
--
作者：
Wakasaki, Takahiro;Yasumatsu, Ryuji;Nakagawa, Takashi
最近的研究表明，免疫检查点抑制剂（ICI）治疗复发性和转移性头颈部鳞状细胞癌（R/M HNSCC）后补救化疗（SCT）的益处。我们回顾性研究了SCT的结果和血清C反应蛋白水平（CRP）和嗜中性粒细胞与淋巴细胞比率（NLR）作为预后生物标志物的有用性。39例R/M HNSCC患者入组本研究。25例患者（64.1%）接受每周紫杉醇和西妥昔单抗（PC）联合化疗作为SCT，14例患者（35.9%）接受替加氟-吉美司他-奥他司他钾（S1），一种口服氟嘧啶。所有患者的缓解率、疾病控制率、中位无进展生存期（PFS）和中位总生存期（OS）分别为45.2%、85.7%、6.5个月和13.5个月。未观察到化疗相关死亡。这些PC组有低CRP（
Recent studies have suggested the benefit of salvage chemotherapy (SCT) after immune checkpoint inhibitor (ICI) treatment for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). We retrospectively examined the outcome of SCT and the usefulness of the serum C-reactive protein level (CRP) and neutrophil-to-lymphocyte ratio (NLR) as prognostic biomarkers. Thirty-nine patients with R/M HNSCC were enrolled in this study. Twenty-five patients (64.1%) received combination chemotherapy of weekly paclitaxel and cetuximab (PC) as SCT, and 14 patients (35.9%) received tegafur-gimestat-otastat potassium (S1), an oral fluoropyrimidine. In all patients, the response rate, disease control rate, median progression-free survival (PFS), and median overall survival (OS) were 45.2%, 85.7%, 6.5 months, and 13.5 months, respectively. No chemotherapy-related deaths were observed. These PC groups had low CRP (